Section Arrow
HCWB.NASDAQ
- HCW Biologics
Quotes are at least 15-min delayed:2024/06/25 01:33 EDT
Last
 0.8002
+0.0773 (+10.69%)
Day High 
1.16 
Prev. Close
0.7229 
1-M High
1.2158 
Volume 
399.55K 
Bid
0.76
Ask
0.79
Day Low
0.75 
Open
0.874951 
1-M Low
0.7229 
Market Cap 
27.34M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.03 
20-SMA 1.05 
50-SMA 1.23 
52-W High 2.32 
52-W Low 0.7229 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.76/-0.55
Enterprise Value
33.65M
Balance Sheet
Book Value Per Share
0.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.84M
Operating Revenue Per Share
0.10
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.3662-0.0582-13.71%-- 
REVBRevelation Biosciences2.37+0.26+12.32%-- 
GLYCGlycoMimetics0.2648+0.0075+2.91%-- 
ALTAltimmune7.135+0.725+11.31%-- 
MBIOMustang Bio0.5703+0.015+2.70%-- 
Quotes are at least 15-min delayed:2024/06/25 01:33 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.